S&P 500 rises as health care, tech gain to overshadow Fed independence concerns
On Wednesday, Deutsche Bank (ETR:DBKGn) analysts resumed coverage of Ipsen (EPA:IPN) SA stock with a Buy rating, setting a price target of €122.00. The analysts highlighted the continued strong performance of Ipsen’s Somatuline, which has outperformed company consensus for the last four quarters.
The analysts attributed Somatuline’s success to the challenges faced by generic competitors in maintaining a steady supply. They noted that even if generic supply resumes, the impact on Somatuline sales is not expected to be immediate.
Deutsche Bank also pointed out the increasing investor interest in Ipsen’s long-acting neurotoxin (LANT). The analysts expressed a positive risk-reward view on the likelihood of proof-of-concept (PoC) success for this product.
The analysts’ coverage resumption reflects confidence in Ipsen’s strategic positioning and product pipeline, particularly in the face of competitive pressures in the pharmaceutical market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.